Long-term Enjaymo Use in 4 Women With CAD Deemed Safe, Effective - Cold Agglutinin News

Enjaymo led to hemoglobin gains and cut the need for blood transfusions in four women with cold agglutinin disease, according to trial data.

Enjaymo (sutimlimab) quickly led to increases in hemoglobin and lowered the need for blood transfusions in four women with cold agglutinin disease (CAD), in whom the treatment remained safe and effec… [+4089 chars]

full article...